Want to see CH:DOCM full AI Analyst Report?
DOCM Stock Chart & Stats
CHF6.61
CHF0.36(1.86%)
At close: 4:00 PM EST
CHF6.61
CHF0.36(1.86%)
Day’s Range― - ―
52-Week RangeCHF3.92 - CHF8.78
Previous CloseN/A
Volume45.75K
Average Volume (3M)342.18K
Market Cap
CHF402.45M
Enterprise ValueCHF581.69M
Total Cash (Recent Filing)CHF149.92M
Total Debt (Recent Filing)CHF288.64M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.60
Shares Outstanding52,007,114
10 Day Avg. Volume377,518
30 Day Avg. Volume342,178
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.75
Price to Sales (P/S)0.27
P/FCF Ratio-3.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF6.50Price Target Upside-1.66% Downside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-1.76
Revenue Forecast (FY)CHF1.21B
Bulls Say, Bears Say
Bulls Say
High-margin Digital ServicesRapid, high-margin Digital Services growth creates a durable revenue stream that scales with low incremental capex. At 110% growth and strong take-rates from TeleClinic and Retail Media, these services materially improve CM3 and provide a structural lever to drive EBITDA and FCF as scale expands.
Large Customer Platform And RetentionA roughly 11M active-customer base with rising order frequency and high repeat rates builds durable revenue visibility and cross-sell potential. Recurring Rx demand and improving retention increase lifetime value, supporting stable top-line growth and more predictable margin expansion over the medium term.
Improved Liquidity And LeverageMaterial liquidity and a markedly improved equity ratio reduce short-term refinancing pressure and give management runway to execute operational fixes. Lower net debt and clarified near-term maturities support investments in digital initiatives and provide buffer while working toward EBITDA/FCF break‑even targets.
Bears Say
Sustained Negative Cash FlowPersistent and worsening negative operating and free cash flow is a structural risk: it depletes liquidity, forces external financing or asset disposals, and constrains investments in growth initiatives. Even with current liquidity, continued cash burn raises refinancing and dilution risk before FCF turn.
Large Adjusted EBITDA LossesSignificant ongoing EBITDA deficits undermine margin sustainability and make the path to durable profitability contingent on execution. The company must deliver CM3 improvements and cost discipline as guided; failure to do so would prolong cash burn and weaken operational flexibility.
Logistics And Working-capital WeaknessesRising logistics costs and material working-capital inefficiencies directly erode gross margins and cash conversion. Structural delivery cost pressure plus inventory/receivables slippage raise ongoing operating expense and liquidity needs, making margin recovery and free‑cash‑flow targets harder to achieve.
DOCM FAQ
What was DocMorris AG’s price range in the past 12 months?
DocMorris AG lowest stock price was CHF3.92 and its highest was CHF8.78 in the past 12 months.
What is DocMorris AG’s market cap?
DocMorris AG’s market cap is CHF402.45M.
When is DocMorris AG’s upcoming earnings report date?
DocMorris AG’s upcoming earnings report date is Aug 19, 2026 which is in 50 days.
How were DocMorris AG’s earnings last quarter?
Currently, no data Available
Is DocMorris AG overvalued?
According to Wall Street analysts DocMorris AG’s price is currently Overvalued.
Does DocMorris AG pay dividends?
DocMorris AG does not currently pay dividends.
What is DocMorris AG’s EPS estimate?
DocMorris AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does DocMorris AG have?
DocMorris AG has 52,007,114 shares outstanding.
What happened to DocMorris AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of DocMorris AG?
Currently, no hedge funds are holding shares in CH:DOCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DocMorris AG
DocMorris AG is a key player in the pharmaceutical sector, focusing on both online pharmacy services and the wholesale supply of medical and pharmaceutical goods. The company provides a comprehensive selection of items, including prescription and over-the-counter medications, health and wellness products, beauty and personal care lines, dietary supplements, pain relief remedies, and emergency first aid supplies. Furthermore, it offers specialized medication management support. In addition to its significant digital footprint, DocMorris AG also operates traditional brick-and-mortar pharmacy locations. Its commercial activities extend across Switzerland and into various international territories, serving medical practitioners, other online pharmaceutical distributors, and individual consumers directly. Notable brands within its portfolio include Zur Rose, PromoFarma, TeleClinic, and DocMorris. Established in 1993 and based in Frauenfeld, Switzerland, the company adopted its current name, DocMorris AG, in May 2023, having previously been known as Zur Rose Group AG.
DOCM Stock 12 Month Forecast
Average Price Target
CHF6.50
▼(-1.66% Downside)
Technical Analysis
Idorsia Ltd
―
Santhera Pharmaceuticals Holding
―
Galenica AG
―
Galderma Group AG
―
medmix AG
―
Options Prices
Currently, No data available
---